Since p53 is mutated in approximately 75% of pancreatic tumors and as no standard therapies based on mutp53 are available, a better knowledge of the molecular mechanisms that regulate its degradation is of fundamental importance for developing new therapeutic strategies. The gene discussed is TP53; the disease is pancreatic neoplasm.